Glenmark now India's fourth-largest pharmaceutical company, in 1977, the first to enter the drug market in dermatology drug, with independent research and development center, set up production facilities in conformity with the FDA standard, established the development in the United States and Switzerland respectively the manufacturer of injection oral preparations and biological agents, and engaged in diversified API production and business operation.
Biosplice Therapeutics, inc. (NYSE: Biosplice) is a U.S. biotech company focused on innovative clinical-stage medicines that provide selective precursor mRNA splicing based therapies for critical diseases. The company is currently developing the first small molecule therapy based on selective precursor mRNA shearing.
Starton is a clinical-stage biotech company that aims to change the standard of existing nursing therapies. The company focuses on transdermal patches, screening best-selling drugs that have been approved for many years, developing new dosage forms or new indications based on their rich clinical use base and data, and reducing drug development time and risk through the 505(b)2 filing pathway.